LIXTE Announces Three-Way Clinical Trial Agreement With GSK and MD Anderson

Seattle – September 20, 2023 – Cooley advised Lixte Biotechnology, a clinical-stage pharmaceutical company focused on developing and commercializing new cancer therapies, on its clinical trial agreement with The University of Texas MD Anderson Cancer Center and GSK. Lawyers Alison Freeman-Gleason and Matthew Langer led the Cooley team advising LIXTE.

The clinical trial will assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1) blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma. The clinical trial is sponsored by and will be conducted at the MD Anderson Cancer Center and also will be open at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. LIXTE will provide LB-100, while GSK will provide dostarlimab and financial support for the clinical trial.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.